{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:43:51Z","timestamp":1785797031726,"version":"3.56.0"},"reference-count":56,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite enormous improvement in the management of patients with acute promyelocytic leukemia (APL), the distinctive coagulopathy observed at presentation in affected patients is often life-threatening. While hemorrhagic manifestations are well known and described in this setting, APL-related thromboses are underappreciated. Data regarding this complication are scarce showing variable incidence. Furthermore, risk factors for thrombosis are inconsistent and unreliable; so, differentiation of increased risk of hemorrhage from an increased thrombotic risk is quite difficult in the absence of adequate predictive scores. Besides, prophylactic use of anticoagulants and recombinant thrombomodulin are a matter of ongoing debate. Also, due to the common feature of thrombocytopenia and other hemorrhagic risks, patients with APL are excluded from trials analyzing anticoagulant prophylaxis in cancers; so, data from prospective trials are lacking. A detailed analysis of thrombotic risks in APL with the development of a reliable risk stratification model is needed to further improve the care of APL patients.<\/jats:p>","DOI":"10.1055\/a-2238-4782","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T20:01:10Z","timestamp":1710187270000},"page":"457-464","source":"Crossref","is-referenced-by-count":9,"title":["Thrombosis in Acute Promyelocytic Leukemia: The Current Understanding"],"prefix":"10.1055","volume":"45","author":[{"given":"Nikica","family":"Sabljic","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Center of Serbia, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Mitrovic","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Center of Serbia, Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Pantic","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, University Clinical Center of Serbia, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jecko","family":"Thachil","sequence":"additional","affiliation":[{"name":"Department of Hematology, Manchester Royal Infirmary, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"issue":"25","key":"ref1","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2009-07-216457","article-title":"How I treat acute promyelocytic leukemia","volume":"114","author":"M S Tallman","year":"2009","journal-title":"Blood"},{"issue":"S 01","key":"ref2","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.thromres.2018.01.041","article-title":"Mechanisms and management of coagulopathy in acute promyelocytic leukemia","volume":"164","author":"S David","year":"2018","journal-title":"Thromb Res"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.clml.2022.11.005","article-title":"Improvement of early death in acute promyelocytic leukemia: a population-based analysis","volume":"23","author":"G Li","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"09","key":"ref4","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1182\/blood-2002-02-0352","article-title":"Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up","volume":"100","author":"G Avvisati","year":"2002","journal-title":"Blood"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12032-013-0478-y","article-title":"International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation \u2265 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia","volume":"30","author":"M Mitrovic","year":"2013","journal-title":"Med Oncol"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12885-023-10612-z","article-title":"Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021","volume":"23","author":"H Gill","year":"2023","journal-title":"BMC Cancer"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2011.08922.x","article-title":"The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia","volume":"156","author":"K A Breen","year":"2012","journal-title":"Br J Haematol"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.thromres.2004.11.001","article-title":"Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients","volume":"116","author":"N Dally","year":"2005","journal-title":"Thromb Res"},{"issue":"09","key":"ref9","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1538-7836.2005.01467.x","article-title":"The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment","volume":"3","author":"V De Stefano","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.leu.2404377","article-title":"Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features","volume":"21","author":"M Breccia","year":"2007","journal-title":"Leukemia"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors","volume":"113","author":"P Montesinos","year":"2009","journal-title":"Blood"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000345833","article-title":"Acute promyelocytic leukemia-associated thrombosis","volume":"130","author":"H Chang","year":"2013","journal-title":"Acta Haematol"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.thromres.2014.11.026","article-title":"Thrombotic events in acute promyelocytic leukemia","volume":"135","author":"M Mitrovic","year":"2015","journal-title":"Thromb Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2019.02.007","article-title":"The value of FDP\/FIB and D-dimer\/FIB ratios in predicting high-risk APL-related thrombosis","volume":"79","author":"Y Bai","year":"2019","journal-title":"Leuk Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.thromres.2021.12.020","article-title":"Predictive factors for differentiating thrombohemorrhagic disorders in high-risk acute promyelocytic leukemia","volume":"210","author":"M Xiao","year":"2022","journal-title":"Thromb Res"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12959-021-00294-7","article-title":"Risk factors of thrombosis in Chinese subjects with acute promyelocytic leukemia","volume":"19","author":"X Zhang","year":"2021","journal-title":"Thromb J"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1097\/01.HS9.0000850060.85301.70","article-title":"PB1802: Acute promyelocytic leukemia and thrombosis: How to identify the high-risk patients?","volume":"6","author":"M Ben Salah","year":"2022","journal-title":"HemaSphere"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00277-022-04770-6","article-title":"Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study","volume":"101","author":"F Martella","year":"2022","journal-title":"Ann Hematol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1097\/01.HS9.0000849624.24408.8e","article-title":"P1692: Predictive model for vein thromboembolic events developed in patients with acute myeloid leukemia","volume":"6","author":"M Mitrovic","year":"2022","journal-title":"HemaSphere"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/CCO.0000000000000402","article-title":"Thrombosis in adult patients with acute leukemia","volume":"29","author":"M I Del Principe","year":"2017","journal-title":"Curr Opin Oncol"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2141.2005.05529.x","article-title":"Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study","volume":"129","author":"A Cortelezzi","year":"2005","journal-title":"Br J Haematol"},{"issue":"02","key":"ref22","first-page":"1673","article-title":"A prospective study of the use of central venous catheters in patients newly diagnosed with acute myeloid leukemia treated with induction chemotherapy","volume":"30","author":"C McKeown","year":"2022","journal-title":"Support Care Cancer"},{"issue":"15","key":"ref23","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"M A Sanz","year":"2019","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3109\/10428199609052425","article-title":"Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid","volume":"20","author":"S M Escudier","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"101522","DOI":"10.1016\/j.tranon.2022.101522","article-title":"Evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: a real-world analysis of 1105 patients over the last three decades","volume":"25","author":"S Teng-Fei","year":"2022","journal-title":"Transl Oncol"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"A A Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/00325481.2020.1863717","article-title":"Trends and outcomes of venous thromboembolism in adult hospitalizations with acute myeloid leukemia: analysis of nationwide inpatient sample from 2010 to 2014","volume":"133","author":"S Khadka","year":"2021","journal-title":"Postgrad Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2020.12.032","article-title":"Venous-thromboembolism in elderly patients with acute myeloid leukemia","volume":"200","author":"R Gangaraju","year":"2021","journal-title":"Thromb Res"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00277-023-05158-w","article-title":"The occurrence of thrombosis during intensive chemotherapy treatment for acute myeloid leukemia patients does not impact on long-term survival","volume":"102","author":"T Hellou","year":"2023","journal-title":"Ann Hematol"},{"issue":"22","key":"ref30","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.3390\/cancers14225640","article-title":"Predictors of early thrombotic events in adult patients with acute myeloid leukemia: a real-world experience","volume":"14","author":"G Paterno","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.3390\/cancers15113060","article-title":"Arterial thrombosis in patients with acute myeloid leukemia: incidence and risk factors","volume":"15","author":"M Mitrovic","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjh.17388","article-title":"Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study","volume":"193","author":"F A Orsi","year":"2021","journal-title":"Br J Haematol"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/jth.13265","article-title":"The influence of corticosteroids on hemostasis in healthy subjects","volume":"14","author":"C J Majoor","year":"2016","journal-title":"J Thromb Haemost"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12959-019-0202-z","article-title":"Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience","volume":"17","author":"A S Mirza","year":"2019","journal-title":"Thromb J"},{"issue":"02","key":"ref35","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1055\/s-0039-3400303","article-title":"Development of a clinical prediction rule for venous thromboembolism in patients with acute leukemia","volume":"120","author":"F Al-Ani","year":"2020","journal-title":"Thromb Haemost"},{"issue":"S 01","key":"ref36","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S0049-3848(20)30399-6","article-title":"Advances in the management of coagulopathy in acute promyelocytic leukemia","volume":"191","author":"M A Sanz","year":"2020","journal-title":"Thromb Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"722614","DOI":"10.3389\/fmed.2021.722614","article-title":"Coagulopathy in acute promyelocytic leukemia: Can we go beyond supportive care?","volume":"8","author":"B C Hambley","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"06","key":"ref38","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00277-021-04533-9","article-title":"Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study","volume":"100","author":"H Zhao","year":"2021","journal-title":"Ann Hematol"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/s-0037-1615693","article-title":"Effect of intradermal tumor necrosis factor-alpha-induced inflammation on coagulation factors in dermal vessel endothelium. An in vivo study of human skin biopsies","volume":"85","author":"W Speiser","year":"2001","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref40","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1161\/01.RES.0000171805.24799.fa","article-title":"Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines","volume":"96","author":"B Szotowski","year":"2005","journal-title":"Circ Res"},{"issue":"12","key":"ref41","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1016\/S0021-9258(18)60636-2","article-title":"Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor","volume":"263","author":"R R Schleef","year":"1988","journal-title":"J Biol Chem"},{"issue":"05","key":"ref42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.thromres.2004.10.010","article-title":"Effects of TNF-alpha and curcumin on the expression of thrombomodulin and endothelial protein C receptor in human endothelial cells","volume":"115","author":"B Nan","year":"2005","journal-title":"Thromb Res"},{"issue":"09","key":"ref43","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood.V91.9.3093","article-title":"The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia","volume":"91","author":"T Barbui","year":"1998","journal-title":"Blood"},{"issue":"10","key":"ref44","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1055\/s-0039-1693737","article-title":"All-trans retinoic acid impairs platelet function and thrombus formation and inhibits protein kinase C\u00dfI\/\u03b4 phosphorylation","volume":"119","author":"Q Luo","year":"2019","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref45","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/ajh.23158","article-title":"Bleeding and thrombosis in acute promyelocytic leukemia","volume":"87","author":"A Choudhry","year":"2012","journal-title":"Am J Hematol"},{"issue":"21","key":"ref46","doi-asserted-by":"crossref","first-page":"pe25","DOI":"10.1126\/stke.121pe25","article-title":"ETosis: a novel cell death pathway","volume":"1","author":"F Wartha","year":"2008","journal-title":"Sci Signal"},{"issue":"02","key":"ref47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41419-017-0018-3","article-title":"Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy","volume":"9","author":"T Li","year":"2018","journal-title":"Cell Death Dis"},{"issue":"11","key":"ref48","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1111\/j.1538-7836.2011.04465.x","article-title":"Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus","volume":"9","author":"L L Swystun","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref49","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00464-006-9179-3","article-title":"Coagulation status and the presence of postoperative deep vein thrombosis in patients undergoing laparoscopic cholecystectomy","volume":"21","author":"D J Milic","year":"2007","journal-title":"Surg Endosc"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.cca.2021.06.019","article-title":"Comparison between thromboelastography and conventional coagulation assays in patients with deep vein thrombosis","volume":"520","author":"C Mao","year":"2021","journal-title":"Clin Chim Acta"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/TA.0000000000001618","article-title":"The rate of deep vein thrombosis doubles in trauma patients with hypercoagulable thromboelastography","volume":"83","author":"J B Brill","year":"2017","journal-title":"J Trauma Acute Care Surg"},{"issue":"02","key":"ref52","first-page":"266","article-title":"Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time","volume":"67","author":"M S Park","year":"2009","journal-title":"J Trauma"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/00365510600672783","article-title":"Whole blood thrombelastographic coagulation profiles using minimal tissue factor activation can display hypercoagulation in thrombosis-prone patients","volume":"66","author":"L Hvitfeldt Poulsen","year":"2006","journal-title":"Scand J Clin Lab Invest"},{"issue":"04","key":"ref54","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"S V Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"01","key":"ref55","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12185-013-1463-0","article-title":"Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin","volume":"100","author":"T Ikezoe","year":"2014","journal-title":"Int J Hematol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.thromres.2021.04.003","article-title":"Efficacy of recombinant human soluble thrombomodulin in induction therapy for acute promyelocytic leukemia","volume":"202","author":"K Matsuda","year":"2021","journal-title":"Thromb Res"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2238-4782.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T23:30:46Z","timestamp":1767915046000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2238-4782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":56,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2025,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2238-4782","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]}}}